bioAffinity Technologies, Inc. received a notice from Nasdaq on July 30, 2026, indicating non-compliance with the minimum bid price requirement due to its common stock closing below $1.00 for thirty consecutive business days ending July 29, 2026. The company is ineligible for the standard 180-day cure period because it executed a 1-for-30 reverse stock split on September 19, 2025. bioAffinity intends to appeal this determination on August 6, 2026, which will stay any delisting or suspension pending the Panel's decision. The company operates in the biotechnology industry.

bioAffinity Technologies, Inc. announced the publication of a clinical review and white paper by Chief Medical Officer Gordon H. Downie, MD, PhD, which presents a clinical framework for using CyPath Lung to evaluate pulmonary nodules and cancer surveillance. The publication discusses how the test's lung microenvironment analysis via sputum collection is integrated into primary care, pulmonology, and oncology practices. bioAffinity Technologies, Inc. is a biotechnology company focused on noninvasive diagnostics and early cancer detection.